Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
28 déc. 2022 07h00 HE
|
BIOXYTRAN, INC.
Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28,...
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
14 déc. 2022 07h00 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...
Bioxytran Interview at the Emerging Growth Conference
12 déc. 2022 09h45 HE
|
BIOXYTRAN, INC.
Wednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
08 déc. 2022 07h00 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and...
Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics
22 nov. 2022 08h00 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet...
Bioxytran Scientific Advisor Releases New Book on Brain Metabolism
25 oct. 2022 07h00 HE
|
BIOXYTRAN, INC.
The book contains all aspects of brain energy metabolism and other physiological functions related to Cortical Spreading Depression which is the essence of how the brain consumes oxygen. BOSTON,...
Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
01 août 2022 09h00 HE
|
BIOXYTRAN, INC.
ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology...